A Phase 3 interventional study of MSB11022 and EU-Humira in Moderate to Severe Rheumatoid Arthritis, sponsored by Fresenius Kabi SwissBioSim GmbH. Completed at 46 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-20.
Sponsored by Fresenius Kabi SwissBioSim GmbH (part of Fresenius Kabi) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 34th largest by enrollment, is the only one that started in 2017, is one of 36 in phase 3, and was the 75th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 288 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
This study is registered under Fresenius Kabi SwissBioSim GmbH, one of the names counted as Fresenius Kabi. Under that name alone:
Fresenius Kabi SwissBioSim GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Fresenius Kabi has 8 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult participants with rheumatoid arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MSB11022
Drug: EU-Humira
Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
Also known as: Adalimumab
Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)
Adverse event (AE) was defined as any untoward medical occurrence in participants, which does not necessarily have causal relationship with treatment. Term Treatment-emergent Adverse Events (TEAE) is defined as AEs starting/worsening after first intake of the study drug. Hypersensitivity was the pre-defined TEAE of special Interest for this study. The percentage of participants with treatment emergent AESIs (hypersensitivity) were reported.
Time frame: Up to Week 52
Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 12
The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), participant's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).
Time frame: Week 12
Percentage of Participants With Positive Anti-Drug Antibodies (ADAs) Status to Adalimumab
Percentage of participants with positive anti-Drug antibodies (ADAs) status to Adalimumab were reported.
Time frame: Baseline, Week 2, 4, 12, 24, 36 and 52
Anti-Drug Antibodies (ADAs) Titer Levels for Adalimumab
Titer was defined as the degree to which the antibody-serum sample could be diluted and still contained detectable amounts of antibody. Anti-Drug Antibodies (ADAs) titers for adalimumab was reported. Data was collected using validated bioanalytical method.
Time frame: Baseline, Week 2, 4, 12, 24, 36 and 52
Percentage of Participants With Confirmed Neutralizing Antibodies (NAb) Status to Adalimumab
Percentage of participants with confirmed neutralizing antibodies status to Adalimumab were reported.
Time frame: Baseline, Week 2, 4, 12, 24, 36 and 52
Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 2, 4, 8, 24 and 52
The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).
Time frame: Week 2, 4, 8, 24 and 52
Percentage of Participants Who Achieved American College of Rheumatology 50 (ACR50) Response at Week 2, 4, 8, 12, 24 and 52
The ACR 50 Response is defined as greater than or equal to (\>=) 50 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=50 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).
Time frame: Week 2, 4, 8, 12, 24 and 52
Percentage of Participants Who Achieved American College of Rheumatology 70 (ACR70) Response at Week 2, 4, 8, 12, 24 and 52
The ACR 70 Response is defined as greater than or equal to (\>=) 70 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=70 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).
Time frame: Week 2, 4, 8, 12, 24 and 52
Change From Baseline in Disease Activity Score Based on a 28 Joint Count- Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 2, 4, 8, 12, 24 and 52
DAS calculated on 28 joints is composite score derived from 4 measures: number of swollen joints (out of 28), number of tender joints (out of 28), Erythrocyte sedimentation rate (ESR), Patient's Global Assessment of Disease Activity on visual analog scale (VAS). Overall disease activity score DAS28 was derived using following formulas from DAS28:DAS28=0.56\*√(TJC28)+0.28\*√(SJC28) + 0.014\*GH+0.70\*ln(ESR). Where: TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, ln(ESR) = natural log of ESR, GH = general health component of DAS (ie, Patient's Global Assessment of Disease Activity, assessed using scale of 1-100 where 100 is maximal activity); For analyses, GH divided by 10 \& converted to 0.5 scale, i.e, 0, 0.5, 1, 1.5. DAS28-ESR of \>5.1 implies active disease, \<3.2 low disease activity, \& \<2.6 remission. Change of 1.2(twice measurement error)=significant change of disease activity state. Overall score ranges from 0-10 where higher score means more severe disease.
Time frame: Baseline, Week 2, 4, 8, 12, 24 and 52
Percentage of Participants With Disease Activity Score Based on 28-joints Count- Erythrocyte Sedimentation Rate (DAS28-ESR) Low Disease Activity and Remission at Week 2, 4, 8, 12, 24, and 52
Disease Activity Score calculated on 28 joints is composite score derived from 4 measures: number of swollen joints (out of 28), -number of tender joints (out of 28), -Erythrocyte sedimentation rate (ESR), -Patient's Global Assessment of Disease Activity on visual analog scale (VAS). Overall disease activity score DAS28 was derived using following formulas from DAS28: DAS28=0.56\*√(TJC28)+0.28\*√(SJC28) + 0.014\*GH+0.70\*ln(ESR). Where: -TJC28 = 28 joint count for tenderness, -SJC28 = 28 joint count for swelling, -ln(ESR) = natural logarithm of ESR, -GH = general health component of DAS (ie, Patient's Global Assessment of Disease Activity, assessed using scale of 1 to 100 where 100 is maximal activity); For analyses, GH was divided by 10 and converted to a 0.5 scale, i.e., 0, 0.5, 1, 1.5. DAS28-ESR of \>5.1 implies active disease, \<3.2 low disease activity, and \<2.6 remission.
Time frame: Week 2, 4, 8, 12, 24, and 52
Change From Baseline in Simplified Disease Activity Index (SDAI) Total Score at Week 2, 4, 8, 12, 24, and 52
SDAI is numerical sum of 5 outcome parameters: tender \& swollen joint count (based on 28-joint assessment), Patient's \& Physician's Global Assessment of Disease Activity (VAS) \& level of C-reactive protein (CRP)(milligram per deciliter (mg/dL), normal\<1 mg/dL). SDAI was calculated based on following formula: SDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28)+GH+PGA+CRP Where: -GH =general health component of DAS (i.e. Patient's Global Assessment of Disease Activity, assessed using scale of 1 to 100 where 100 is maximal activity; For analyses, GH was divided by 10 \& converted to 0.5 scale (0, 0.5, 1, 1.5).-PGA = Physician's Global Assessment of Disease Activity assessed using scale of 1 to 100 where 100 is maximal activity. For analyses, PGA will be divided by 10 \& converted to 0.5 scale (0, 0.5, 1, 1.5). where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc. The total score range is 0-86 \& lower score indicates less disease activity.
Time frame: Baseline, Week 2, 4, 8, 12, 24, and 52
Change From Baseline in Clinical Disease Activity Index (CDAI) Total Score at Week 2, 4, 8, 12, 24 and 52
Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA. Where, -GH = general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity, assessed using a scale of 1 to 100 where 100 is maximal activity; for analyses, GH was divided by 10 and converted to a 0.5 scale, i.e., 0, 0.5, 1, 1.5 etc. where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc.). -PGA = Physician's Global Assessment of Disease Activity assessed using a scale of 1 to 100 where 100 is maximal activity. For analyses, PGA was divided by 10 and converted to a 0.5 scale, ie, 0, 0.5, 1, 1.5 etc. where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc. The CDAI ranges from 0 to 76. Lower score indicates less disease activity.
Time frame: Baseline, Week 2, 4, 8, 12, 24 and 52
Percentage of Participants With American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission at Week 2, 4, 8, 12, 24 and 52
According to Boolean-based definition of remission of ACR/EULAR, a participant must satisfy all of the following: tender joint count \<= 1, swollen joint count \<= 1, CRP \<= 1 mg/dL, and Patient's Global Assessment of Disease Activity \<= 1 (0 to 10 VAS). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition.
Time frame: Week 2, 4, 8, 12, 24 and 52
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death
Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. All abnormal physical examinations occurring during the study have been reported as Adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to Week 69
Percentage of Participants With Clinically Meaningful Differences in Vital Signs
Vital signs including body temperature, respiratory rate, and heart rate (after 5-minute rest) were measured. Percentage of participants with clinically meaningful abnormalities in vital signs were reported. Clinical meaningful was determined by the investigator.
Time frame: Up to Week 52
Percentage of Participants With Clinically Meaningful Differences in Laboratory Values
Laboratory parameters including hematology, urinalysis, and biochemistry analysis were analyzed.
Time frame: Up to Week 52
Percentage of Participants With Clinically Significant Abnormal Values for 12-lead Electrocardiogram (ECG) at Week 12, 24, and 52
Percentage of participants with clinically significant abnormal values for 12-lead electrocardiogram (ECG) at week 12, 24, and 52 were reported.
Time frame: Week 12, 24, and 52
Percentage of Participants With Anti-Nuclear Antibody (ANA) and Anti Double-stranded Deoxyribonucleic Acid (Anti-dsDNA) at Baseline, Week 24 and 52
For ANA, positivity is defined as any participant with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participant with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL. Percentage of participants with anti-nuclear antibody (ANA) and anti double-stranded deoxyribonucleic acid (Anti-dsDNA) at baseline, week 24 and 52 were reported.
Time frame: Baseline, Week 24 and 52
Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 12, 24 and 52
The HAQ-DI is a participant-reported questionnaire that is commonly used in RA to measure disease associated disability (assessment of physical function). It consists of several questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. HAQ-DI scores range from 0 to 3. The disability section of the questionnaire scores the participant's self-perception on the degree of difficulty (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do).
Time frame: Baseline, Weeks 12, 24 and 52
Short-Form Health Survey- 36 Items (SF-36) at Baseline, Week 12, 24 and 52
The Short Form Health Survey (SF-36) is a validated 36-item, patient-reported indication of overall health status not specific to any age, disease or Treatment group. The SF-36 questionnaire contains 36 questions pertaining to eight subscales of health status. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) is based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100=highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning).
Time frame: Baseline, Week 12, 24 and 52
Euro-Quality of Life - 5 Dimension-5 Levels (EQ-5D-5L) Utility Index Score at Baseline, Week 12, 24 and 52
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm.
Time frame: Baseline, Week 12, 24 and 52
Euro-Quality of Life - 5 Dimension-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Baseline, Week 12, 24 and 52
EQ-5D-5L: Standardized, participant-rated questionnaire to assess health-related quality of life. EQ-5D-5L includes 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L Visual Analog Scale. EQ-5D-5L descriptive system provides a profile of participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. Responses to 5 dimension scores were combined and converted into single preference-weighted health utility index score 0 (worst health state) to 1 (better health state). EQ-VAS: Self-rated health status using a vertical VAS. EQ-VAS records participant's perceptions of their own current overall health in range from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: Baseline, Week 12, 24 and 52
Mean Change From Baseline (Week 4) in Injection Site Pain as Assessed by Visual Analogue Scale (VAS) at Week 6 and 8
The participant's reported perception of pain was measured on a VAS where the slash drawn by the participant represents pain of increasing intensity. VAS score ranges from 0-10 millimeter \[mm\], where; 0 mm=no pain and 10 mm=worst possible pain. The first 2 injections was administered by qualified personnel. The next three doses of IMP (3-5) will be self-administered by the participant and injection site pain was assessed. Pain was recorded immediately after, 15 minutes after, and 1 hour after the injections received by the participants.
Time frame: Immediately, 15 minutes and 1 hour post-injection on Baseline (Week 4), Week 6 and 8
| Milestone | MSB11022 | EU-Humira |
|---|---|---|
| Started | 143 | 145 |
| Completed | 122 | 113 |
| Not completed | 21 | 32 |
| Withdrew: Other un-specified | 1 | 2 |
| Withdrew: Withdrawal by subject | 10 | 9 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Adverse event | 6 | 13 |
Adverse event (AE) was defined as any untoward medical occurrence in participants, which does not necessarily have causal relationship with treatment. Term Treatment-emergent Adverse Events (TEAE) is defined as AEs starting/worsening after first intake of the study drug. Hypersensitivity was the pre-defined TEAE of special Interest for this study. The percentage of participants with treatment emergent AESIs (hypersensitivity) were reported.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI) | 4.2 (1.6 to 8.9) | 5.5 (2.4 to 10.6) |
The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), participant's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 12 | 79.6 (72.0 to 85.9) | 80.9 (73.4 to 86.9) |
Percentage of participants with positive anti-Drug antibodies (ADAs) status to Adalimumab were reported.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Baseline | 7.7 | 4.2 |
| Week 2 | 20.3 | 15.2 |
| Week 4 | 29.8 | 21.3 |
| Week 12 | 54.2 | 48.6 |
| Week 24 | 71.9 | 61.7 |
| Week 36 | 66.9 | 65.3 |
| Week 52 | 60.8 | 62.2 |
Titer was defined as the degree to which the antibody-serum sample could be diluted and still contained detectable amounts of antibody. Anti-Drug Antibodies (ADAs) titers for adalimumab was reported. Data was collected using validated bioanalytical method.
| Titer | MSB11022 | EU-Humira |
|---|---|---|
| Baseline | 4.0 (1 to 512) | 1.5 (1 to 8) |
| Week 2 | 4.0 (1 to 32768) | 12.0 (1 to 1024) |
| Week 4 | 6.0 (1 to 16384) | 6.0 (1 to 512) |
| Week 12 | 16.0 (1 to 4096) | 16.0 (1 to 16384) |
| Week 24 | 16.0 (1 to 32768) | 24.0 (1 to 131072) |
| Week 36 | 16.0 (1 to 32768) | 16.0 (1 to 131072) |
| Week 52 | 16.0 (1 to 16384) | 12.0 (1 to 32768) |
Percentage of participants with confirmed neutralizing antibodies status to Adalimumab were reported.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Baseline | 45.5 | 50.0 |
| Week 2 | 31.0 | 40.9 |
| Week 4 | 33.3 | 30.0 |
| Week 12 | 33.8 | 38.2 |
| Week 24 | 27.0 | 29.3 |
| Week 36 | 24.1 | 29.1 |
| Week 52 | 32.9 | 39.2 |
The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Week 2 | 30.0 (22.55 to 38.32) | 29.7 (22.36 to 37.80) |
| Week 4 | 52.1 (43.58 to 60.56) | 52.8 (44.29 to 61.15) |
| Week 8 | 71.1 (62.93 to 78.42) | 72.9 (64.89 to 79.98) |
| Week 24 | 88.5 (81.98 to 93.28) | 83.3 (75.86 to 89.25) |
| Week 52 | 81.8 (73.78 to 88.24) | 86.4 (78.92 to 92.05) |
The ACR 50 Response is defined as greater than or equal to (\>=) 50 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=50 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Week 2 | 6.4 (2.9 to 11.9) | 6.2 (2.9 to 11.5) |
| Week 4 | 17.6 (11.7 to 24.9) | 19.4 (13.3 to 26.9) |
| Week 8 | 40.8 (32.7 to 49.4) | 34.7 (26.9 to 43.1) |
| Week 12 | 54.2 (45.7 to 62.6) | 51.1 (42.5 to 59.6) |
| Week 24 | 65.5 (56.9 to 73.3) | 60.6 (51.7 to 68.9) |
| Week 52 | 64.5 (55.3 to 72.9) | 66.1 (56.8 to 74.6) |
The ACR 70 Response is defined as greater than or equal to (\>=) 70 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=70 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Week 2 | 0.7 (0.0 to 3.9) | 0.7 (0.0 to 3.8) |
| Week 4 | 4.9 (2.0 to 9.9) | 2.8 (0.8 to 6.9) |
| Week 8 | 14.8 (9.4 to 21.7) | 12.5 (7.6 to 19.0) |
| Week 12 | 26.8 (19.7 to 34.8) | 19.9 (13.6 to 27.4) |
| Week 24 | 33.8 (26.0 to 42.3) | 35.6 (27.5 to 44.4) |
| Week 52 | 39.7 (30.9 to 48.9) | 42.4 (33.3 to 51.8) |
DAS calculated on 28 joints is composite score derived from 4 measures: number of swollen joints (out of 28), number of tender joints (out of 28), Erythrocyte sedimentation rate (ESR), Patient's Global Assessment of Disease Activity on visual analog scale (VAS). Overall disease activity score DAS28 was derived using following formulas from DAS28:DAS28=0.56\*√(TJC28)+0.28\*√(SJC28) + 0.014\*GH+0.70\*ln(ESR). Where: TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, ln(ESR) = natural log of ESR, GH = general health component of DAS (ie, Patient's Global Assessment of Disease Activity, assessed using scale of 1-100 where 100 is maximal activity); For analyses, GH divided by 10 \& converted to 0.5 scale, i.e, 0, 0.5, 1, 1.5. DAS28-ESR of \>5.1 implies active disease, \<3.2 low disease activity, \& \<2.6 remission. Change of 1.2(twice measurement error)=significant change of disease activity state. Overall score ranges from 0-10 where higher score means more severe disease.
| Units on a scale | MSB11022 | EU-Humira |
|---|---|---|
| Change at Week 2 | -0.9 ± 0.9 | -0.7 ± 0.9 |
| Change at Week 4 | -1.4 ± 1.1 | -1.2 ± 1.0 |
| Change at Week 8 | -1.9 ± 0.9 | -1.7 ± 1.1 |
| Change at Week 12 | -2.4 ± 1.1 | -2.1 ± 1.2 |
| Change at Week 24 | -2.7 ± 1.0 | -2.3 ± 1.2 |
| Change at Week 52 | -2.8 ± 1.1 | -2.5 ± 1.1 |
Disease Activity Score calculated on 28 joints is composite score derived from 4 measures: number of swollen joints (out of 28), -number of tender joints (out of 28), -Erythrocyte sedimentation rate (ESR), -Patient's Global Assessment of Disease Activity on visual analog scale (VAS). Overall disease activity score DAS28 was derived using following formulas from DAS28: DAS28=0.56\*√(TJC28)+0.28\*√(SJC28) + 0.014\*GH+0.70\*ln(ESR). Where: -TJC28 = 28 joint count for tenderness, -SJC28 = 28 joint count for swelling, -ln(ESR) = natural logarithm of ESR, -GH = general health component of DAS (ie, Patient's Global Assessment of Disease Activity, assessed using scale of 1 to 100 where 100 is maximal activity); For analyses, GH was divided by 10 and converted to a 0.5 scale, i.e., 0, 0.5, 1, 1.5. DAS28-ESR of \>5.1 implies active disease, \<3.2 low disease activity, and \<2.6 remission.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Low Disease Activity: Week 2 | 10.0 (5.6 to 16.2) | 8.3 (4.4 to 14.0) |
| Low Disease Activity: Week 4 | 20.6 (14.2 to 28.2) | 16.0 (10.4 to 23.0) |
| Low Disease Activity: Week 8 | 33.1 (25.4 to 41.5) | 33.3 (25.7 to 41.7) |
| Low Disease Activity: Week 12 | 46.5 (38.1 to 55.0) | 42.6 (34.3 to 51.2) |
| Low Disease Activity: Week 24 | 55.1 (46.4 to 63.5) | 53.8 (44.9 to 62.5) |
| Low Disease Activity: Week 52 | 57.0 (47.7 to 65.9) | 56.8 (47.3 to 65.9) |
| Remission: Week 2 | 3.6 (1.2 to 8.1) | 2.1 (0.4 to 5.9) |
| Remission: Week 4 | 7.8 (3.9 to 13.5) | 6.9 (3.4 to 12.4) |
| Remission: Week 8 | 18.3 (12.3 to 25.7) | 16.0 (10.4 to 23.0) |
| Remission: Week 12 | 29.6 (22.2 to 37.8) | 24.1 (17.3 to 32.0) |
| Remission: Week 24 | 31.2 (23.6 to 39.6) | 34.1 (26.0 to 42.8) |
| Remission: Week 52 | 40.5 (31.7 to 49.8) | 36.4 (27.8 to 45.8) |
SDAI is numerical sum of 5 outcome parameters: tender \& swollen joint count (based on 28-joint assessment), Patient's \& Physician's Global Assessment of Disease Activity (VAS) \& level of C-reactive protein (CRP)(milligram per deciliter (mg/dL), normal\<1 mg/dL). SDAI was calculated based on following formula: SDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28)+GH+PGA+CRP Where: -GH =general health component of DAS (i.e. Patient's Global Assessment of Disease Activity, assessed using scale of 1 to 100 where 100 is maximal activity; For analyses, GH was divided by 10 \& converted to 0.5 scale (0, 0.5, 1, 1.5).-PGA = Physician's Global Assessment of Disease Activity assessed using scale of 1 to 100 where 100 is maximal activity. For analyses, PGA will be divided by 10 \& converted to 0.5 scale (0, 0.5, 1, 1.5). where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc. The total score range is 0-86 \& lower score indicates less disease activity.
| Units on a scale | MSB11022 | EU-Humira |
|---|---|---|
| Change at Week 2 | -11.5 ± 10.6 | -9.1 ± 10.0 |
| Change at Week 4 | -18.0 ± 11.3 | -16.0 ± 10.9 |
| Change at Week 8 | -24.0 ± 10.6 | -21.4 ± 11.0 |
| Change at Week 12 | -27.9 ± 10.8 | -24.7 ± 10.9 |
| Change at Week 24 | -31.4 ± 11.2 | -27.8 ± 10.6 |
| Change at Week 52 | -31.5 ± 11.6 | -29.1 ± 10.8 |
Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA. Where, -GH = general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity, assessed using a scale of 1 to 100 where 100 is maximal activity; for analyses, GH was divided by 10 and converted to a 0.5 scale, i.e., 0, 0.5, 1, 1.5 etc. where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc.). -PGA = Physician's Global Assessment of Disease Activity assessed using a scale of 1 to 100 where 100 is maximal activity. For analyses, PGA was divided by 10 and converted to a 0.5 scale, ie, 0, 0.5, 1, 1.5 etc. where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc. The CDAI ranges from 0 to 76. Lower score indicates less disease activity.
| Units on a scale | MSB11022 | EU-Humira |
|---|---|---|
| Change at Week 2 | -10.8 ± 10.3 | -8.5 ± 9.9 |
| Change at Week 4 | -17.4 ± 11.2 | -15.2 ± 10.7 |
| Change at Week 8 | -23.5 ± 10.6 | -20.6 ± 10.9 |
| Change at Week 12 | -27.4 ± 10.5 | -24.1 ± 10.7 |
| Change at Week 24 | -30.8 ± 10.9 | -27.1 ± 10.7 |
| Change at Week 52 | -31.1 ± 11.2 | -28.5 ± 10.6 |
According to Boolean-based definition of remission of ACR/EULAR, a participant must satisfy all of the following: tender joint count \<= 1, swollen joint count \<= 1, CRP \<= 1 mg/dL, and Patient's Global Assessment of Disease Activity \<= 1 (0 to 10 VAS). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Week 2 | 0.7 (0.0 to 3.9) | 0.0 (0.0 to 2.5) |
| Week 4 | 0.7 (0.0 to 3.9) | 1.4 (0.2 to 5.1) |
| Week 8 | 3.5 (1.2 to 8.0) | 4.2 (1.5 to 8.9) |
| Week 12 | 5.7 (2.5 to 10.9) | 12.1 (7.2 to 18.6) |
| Week 24 | 11.7 (6.8 to 18.3) | 8.4 (4.3 to 14.5) |
| Week 52 | 21.0 (14.1 to 29.4) | 13.6 (7.9 to 21.1) |
Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. All abnormal physical examinations occurring during the study have been reported as Adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| TEAEs | 58.0 | 64.1 |
| Serious TEAEs | 4.9 | 9.7 |
| TEAEs Leading to Death | 0 | 0.7 |
Vital signs including body temperature, respiratory rate, and heart rate (after 5-minute rest) were measured. Percentage of participants with clinically meaningful abnormalities in vital signs were reported. Clinical meaningful was determined by the investigator.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Percentage of Participants With Clinically Meaningful Differences in Vital Signs | 0 | 0 |
Laboratory parameters including hematology, urinalysis, and biochemistry analysis were analyzed.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Percentage of Participants With Clinically Meaningful Differences in Laboratory Values | 0 | 0 |
Percentage of participants with clinically significant abnormal values for 12-lead electrocardiogram (ECG) at week 12, 24, and 52 were reported.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Week 12 | 0 | 0 |
| Week 24 | 0 | 1.5 |
| Week 52 | 0 | 0.8 |
For ANA, positivity is defined as any participant with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participant with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL. Percentage of participants with anti-nuclear antibody (ANA) and anti double-stranded deoxyribonucleic acid (Anti-dsDNA) at baseline, week 24 and 52 were reported.
| Percentage of Participants | MSB11022 | EU-Humira |
|---|---|---|
| Baseline: ANA: Negative | 97.2 | 95.1 |
| Baseline: ANA: Positive | 2.8 | 4.9 |
| Week 24: ANA: Negative | 92.0 | 91.6 |
| Week 24: ANA: Positive | 8.0 | 8.4 |
| Week 52: ANA: Negative | 78.8 | 84.7 |
| Week 52: ANA: Positive | 21.2 | 15.3 |
| Baseline: Anti-dsDNA: Negative | 97.9 | 98.6 |
| Baseline: Anti-dsDNA: Intermediate | 1.4 | 0.7 |
| Baseline: Anti-dsDNA: Positive | 0.7 | 0.7 |
| Week 24: Anti-dsDNA: Negative | 95.7 | 96.2 |
| Week 24: Anti-dsDNA: Intermediate | 2.2 | 3.0 |
| Week 24: Anti-dsDNA: Positive | 2.2 | 0.8 |
| Week 52: Anti-dsDNA: Negative | 95.0 | 97.5 |
| Week 52: Anti-dsDNA: Intermediate | 0.8 | 1.7 |
| Week 52: Anti-dsDNA: Positive | 4.1 | 0.8 |
The HAQ-DI is a participant-reported questionnaire that is commonly used in RA to measure disease associated disability (assessment of physical function). It consists of several questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. HAQ-DI scores range from 0 to 3. The disability section of the questionnaire scores the participant's self-perception on the degree of difficulty (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do).
| Units on a scale | MSB11022 | EU-Humira |
|---|---|---|
| Baseline | 1.6 ± 0.6 | 1.6 ± 0.6 |
| Week 12 | 1.1 ± 0.6 | 1.1 ± 0.6 |
| Week 24 | 1.0 ± 0.6 | 1.0 ± 0.6 |
| Week 52 | 0.9 ± 0.7 | 0.9 ± 0.6 |
The Short Form Health Survey (SF-36) is a validated 36-item, patient-reported indication of overall health status not specific to any age, disease or Treatment group. The SF-36 questionnaire contains 36 questions pertaining to eight subscales of health status. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) is based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100=highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning).
| Units on a scale | MSB11022 | EU-Humira |
|---|---|---|
| PCS: Baseline | 30.3 ± 7.6 | 30.6 ± 7.8 |
| PCS: Week 12 | 39.0 ± 7.9 | 38.6 ± 8.6 |
| PCS: Week 24 | 40.5 ± 8.8 | 40.8 ± 9.1 |
| PCS: Week 52 | 41.8 ± 9.5 | 41.6 ± 9.3 |
| MCS: Baseline | 40.9 ± 13.2 | 43.4 ± 11.7 |
| MCS: Week 12 | 47.4 ± 11.3 | 48.2 ± 11.3 |
| MCS: Week 24 | 49.8 ± 10.8 | 48.8 ± 10.9 |
| MCS: Week 52 | 48.0 ± 10.4 | 49.3 ± 11.5 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm.
| Units on a scale | MSB11022 | EU-Humira |
|---|---|---|
| Baseline | 0.6 ± 0.2 | 0.6 ± 0.2 |
| Week 12 | 0.8 ± 0.1 | 0.8 ± 0.1 |
| Week 24 | 0.8 ± 0.1 | 0.8 ± 0.1 |
| Week 52 | 0.8 ± 0.2 | 0.8 ± 0.1 |
EQ-5D-5L: Standardized, participant-rated questionnaire to assess health-related quality of life. EQ-5D-5L includes 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L Visual Analog Scale. EQ-5D-5L descriptive system provides a profile of participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. Responses to 5 dimension scores were combined and converted into single preference-weighted health utility index score 0 (worst health state) to 1 (better health state). EQ-VAS: Self-rated health status using a vertical VAS. EQ-VAS records participant's perceptions of their own current overall health in range from 0 (worst imaginable health) to 100 (best imaginable health).
| Units on a scale | MSB11022 | EU-Humira |
|---|---|---|
| Baseline | 42.4 ± 18.5 | 45.4 ± 20.4 |
| Week 12 | 64.6 ± 19.6 | 63.2 ± 20.9 |
| Week 24 | 66.2 ± 22.2 | 65.6 ± 24.3 |
| Week 52 | 68.8 ± 21.7 | 69.0 ± 22.7 |
The participant's reported perception of pain was measured on a VAS where the slash drawn by the participant represents pain of increasing intensity. VAS score ranges from 0-10 millimeter \[mm\], where; 0 mm=no pain and 10 mm=worst possible pain. The first 2 injections was administered by qualified personnel. The next three doses of IMP (3-5) will be self-administered by the participant and injection site pain was assessed. Pain was recorded immediately after, 15 minutes after, and 1 hour after the injections received by the participants.
| Millimeter (mm) | MSB11022 | EU-Humira |
|---|---|---|
| Change at Week 6: Immediately post-injection | -1.4 ± 5.12 | -1.3 ± 10.16 |
| Change at Week 6: 15 min post-injection | -0.2 ± 2.67 | 0.4 ± 3.29 |
| Change at Week 6: 1 hour post-injection | 0.0 ± 0.66 | 0.0 ± 2.67 |
| Change at Week 8: Immediately post-injection | -1.7 ± 6.48 | -2.3 ± 10.35 |
| Change at Week 8: 15 min post-injection | -0.3 ± 2.25 | -0.7 ± 4.12 |
| Change at Week 8: 1 hour post-injection | -0.1 ± 0.57 | -0.7 ± 5.43 |
Collected over Up to Week 69. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MSB11022 | 0/143 (0%) | 8/143 (5.6%) | 15/143 (10.5%) |
| EU-Humira | 2/145 (1.4%) | 15/145 (10.3%) | 34/145 (23.4%) |
| Event | MSB11022 | EU-Humira |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/143 | 2/145 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/143 | 2/145 |
| Anaphylactic reactionImmune system disorders | 1/143 | 0/145 |
| Mycobacterium tuberculosis complex test positiveInvestigations | 1/143 | 1/145 |
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 1/143 | 0/145 |
| Synovial cystMusculoskeletal and connective tissue disorders | 1/143 | 0/145 |
| Transient global amnesiaNervous system disorders | 1/143 | 0/145 |
| Device dislocationProduct Issues | 1/143 | 0/145 |
| Arthritis bacterialInfections and infestations | 1/143 | 0/145 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/143 | 1/145 |
| Event | MSB11022 | EU-Humira |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/143 | 13/145 |
| Injection site erythemaGeneral disorders | 4/143 | 12/145 |
| Injection site painGeneral disorders | 2/143 | 10/145 |
| Injection site pruritusGeneral disorders | 1/143 | 8/145 |
| ErythemaSkin and subcutaneous tissue disorders | 2/143 | 8/145 |
| Age, Continuous(Years) | MSB11022 | EU-Humira | Total |
|---|---|---|---|
| Mean | 53.9 ± 11.9 | 54.0 ± 11.0 | 53.9 ± 11.5 |
| Sex: Female, Male(Participants) | MSB11022 | EU-Humira | Total |
|---|---|---|---|
| Female | 108 | 119 | 227 |
| Male | 35 | 26 | 61 |
| Ethnicity (NIH/OMB)(Participants) | MSB11022 | EU-Humira | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 140 | 144 | 284 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MSB11022 | EU-Humira | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 142 | 143 | 285 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in May 2018, 15 months.
Results were first posted in Apr 2019, 10 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 15 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
Fresenius Kabi SwissBioSim GmbH →